Cargando…

Needleless Ablation of Osteoid Osteoma and Osteoblastoma: The Emergent Role of MRgFUS

Osteoblastoma (OB) and osteoid osteoma (OO) are benign bone-forming tumors, with nearly identical basic microscopic features. The main difference is dimension (OO has usually a nidus measuring <2 cm in diameter). In addition, OB is biologically more active than OO, with a tendency to grow in size...

Descripción completa

Detalles Bibliográficos
Autores principales: Cobianchi Bellisari, Flavia, Palumbo, Pierpaolo, Masciocchi, Carlo, Zoccali, Carmine, Barile, Antonio, Arrigoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745067/
https://www.ncbi.nlm.nih.gov/pubmed/35011867
http://dx.doi.org/10.3390/jcm11010128
_version_ 1784630255876571136
author Cobianchi Bellisari, Flavia
Palumbo, Pierpaolo
Masciocchi, Carlo
Zoccali, Carmine
Barile, Antonio
Arrigoni, Francesco
author_facet Cobianchi Bellisari, Flavia
Palumbo, Pierpaolo
Masciocchi, Carlo
Zoccali, Carmine
Barile, Antonio
Arrigoni, Francesco
author_sort Cobianchi Bellisari, Flavia
collection PubMed
description Osteoblastoma (OB) and osteoid osteoma (OO) are benign bone-forming tumors, with nearly identical basic microscopic features. The main difference is dimension (OO has usually a nidus measuring <2 cm in diameter). In addition, OB is biologically more active than OO, with a tendency to grow in size. Historically, treatments have included surgical resection and analgesics, although invasiveness and poor tolerance have led to the current standard of care moving toward interventional radiology, where radiofrequency ablation (RFA) represents the most diffuse technique. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) has recently emerged as another innovative alternative treatment, providing tumor ablation through a needleless and ionizing radiation-free modality. In addition, this technique has the ability to guarantee a very precise and controlled increase in temperature, delivering small amounts of energy that can accurately destroy only the lesion, avoiding healthy surrounding tissues. The present review focuses on MRgFUS as the less invasive, safe, effective, and durable treatment option for the management of osteoid osteoma and osteoblastoma, including a description of technical details, indications and outcomes.
format Online
Article
Text
id pubmed-8745067
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87450672022-01-11 Needleless Ablation of Osteoid Osteoma and Osteoblastoma: The Emergent Role of MRgFUS Cobianchi Bellisari, Flavia Palumbo, Pierpaolo Masciocchi, Carlo Zoccali, Carmine Barile, Antonio Arrigoni, Francesco J Clin Med Review Osteoblastoma (OB) and osteoid osteoma (OO) are benign bone-forming tumors, with nearly identical basic microscopic features. The main difference is dimension (OO has usually a nidus measuring <2 cm in diameter). In addition, OB is biologically more active than OO, with a tendency to grow in size. Historically, treatments have included surgical resection and analgesics, although invasiveness and poor tolerance have led to the current standard of care moving toward interventional radiology, where radiofrequency ablation (RFA) represents the most diffuse technique. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) has recently emerged as another innovative alternative treatment, providing tumor ablation through a needleless and ionizing radiation-free modality. In addition, this technique has the ability to guarantee a very precise and controlled increase in temperature, delivering small amounts of energy that can accurately destroy only the lesion, avoiding healthy surrounding tissues. The present review focuses on MRgFUS as the less invasive, safe, effective, and durable treatment option for the management of osteoid osteoma and osteoblastoma, including a description of technical details, indications and outcomes. MDPI 2021-12-27 /pmc/articles/PMC8745067/ /pubmed/35011867 http://dx.doi.org/10.3390/jcm11010128 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cobianchi Bellisari, Flavia
Palumbo, Pierpaolo
Masciocchi, Carlo
Zoccali, Carmine
Barile, Antonio
Arrigoni, Francesco
Needleless Ablation of Osteoid Osteoma and Osteoblastoma: The Emergent Role of MRgFUS
title Needleless Ablation of Osteoid Osteoma and Osteoblastoma: The Emergent Role of MRgFUS
title_full Needleless Ablation of Osteoid Osteoma and Osteoblastoma: The Emergent Role of MRgFUS
title_fullStr Needleless Ablation of Osteoid Osteoma and Osteoblastoma: The Emergent Role of MRgFUS
title_full_unstemmed Needleless Ablation of Osteoid Osteoma and Osteoblastoma: The Emergent Role of MRgFUS
title_short Needleless Ablation of Osteoid Osteoma and Osteoblastoma: The Emergent Role of MRgFUS
title_sort needleless ablation of osteoid osteoma and osteoblastoma: the emergent role of mrgfus
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745067/
https://www.ncbi.nlm.nih.gov/pubmed/35011867
http://dx.doi.org/10.3390/jcm11010128
work_keys_str_mv AT cobianchibellisariflavia needlelessablationofosteoidosteomaandosteoblastomatheemergentroleofmrgfus
AT palumbopierpaolo needlelessablationofosteoidosteomaandosteoblastomatheemergentroleofmrgfus
AT masciocchicarlo needlelessablationofosteoidosteomaandosteoblastomatheemergentroleofmrgfus
AT zoccalicarmine needlelessablationofosteoidosteomaandosteoblastomatheemergentroleofmrgfus
AT barileantonio needlelessablationofosteoidosteomaandosteoblastomatheemergentroleofmrgfus
AT arrigonifrancesco needlelessablationofosteoidosteomaandosteoblastomatheemergentroleofmrgfus